The value of a model to consider the cost-effectiveness of interventions for the treatment of major depressive disorder in Canada
Coherent Identifier 20.500.12592/05nwzq

The value of a model to consider the cost-effectiveness of interventions for the treatment of major depressive disorder in Canada

2 November 2023

Summary

The value of a model to consider the cost-effectiveness of interventions for the treatment of major depressive disorder in Canada Commentary The value of a model to consider the cost- effectiveness of interventions for the treatment of major depressive disorder in Canada Fiona Clement PhD, Julia Kirkham MD MSc n Cite as: CMAJ 2023 November 14;195:E1518-9. [...] Although understanding the cost- effectiveness of pharmacogenomic testing in MDD is useful, the contribution of the related research is potentially much more Of course, cost-effectiveness is only 1 consideration feeding extensive. [...] intervention is immediately life saving, the impact on quality of Identification of interventions that are both cost saving and life, the number of people eligible for the intervention, the under- improve clinical outcomes is rare.4 One visual presentation of lying baseline health of the treatment-eligible population, the cost-effectiveness analyses is the incremental cost-effectiveness likelihood. [...] In the case of pharmacogenomic testing, that would upper-right quadrant, meaning they are both more effective and be the $121 million to fund the infrastructure for the testing. [...] within primary care from a trusted source within weeks.11 Contributors: Both authors contributed to the conception and The investment of time, human resources and research fund- design of the work, drafted the manuscript, revised it critically for ing into Ghanbarian and colleagues’ model has been immense.3 important intellectual content, gave final approval of the version Now that this Canadian r.

Pages
2
Published in
Canada